COVID-19 is treated with antiviral medications, over-the-counter symptom relief, or hospital-level therapies depending on how severe the illness is. Most people recover at home with basic care, but prescription antivirals can dramatically reduce the risk of hospitalization when started early, particularly for people at higher risk of serious illness.
Prescription Antivirals for Early Treatment
The primary prescription treatment for COVID-19 is Paxlovid (nirmatrelvir/ritonavir), an oral antiviral taken twice daily for five days. In clinical trials, it reduced the risk of hospitalization and death by 87% in unvaccinated patients at higher risk of severe disease. It’s approved for adults and authorized for children aged 12 and older who weigh at least 88 pounds. The key requirement is timing: treatment needs to start within five days of your first symptoms.
Your doctor will consider prescribing Paxlovid if you have one or more risk factors for severe COVID-19. Those risk factors include being over 65 (with risk climbing significantly past 75), not being up to date on vaccinations, having multiple chronic health conditions, or being immunocompromised. You don’t need any special testing before starting it.
Paxlovid does come with significant drug interactions because one of its components affects how your liver processes other medications. If you take certain blood thinners like rivaroxaban, or cholesterol-lowering statins like simvastatin or lovastatin, you cannot take Paxlovid. Your prescriber will review your full medication list before writing the prescription, and in some cases medications can be temporarily paused or swapped.
A second oral option, molnupiravir (Lagevrio), works differently and has fewer drug interactions. It’s less effective than Paxlovid. In its clinical trial, it cut hospitalizations and death roughly in half at an interim look, though the benefit was smaller in the final analysis, reducing the rate from 9.7% to 6.8%. It’s generally reserved for situations where Paxlovid isn’t an option.
Remdesivir (Veklury), originally developed as a hospital infusion, can also be used for outpatients at high risk. It requires intravenous delivery over three consecutive days, which makes it less convenient than pills. It’s typically used when both oral antivirals are contraindicated.
Managing Mild COVID at Home
Most people with COVID-19 have mild illness and recover at home without prescription medication. Over-the-counter options like acetaminophen (Tylenol) and ibuprofen (Advil, Motrin) help manage fever, body aches, and headache. Staying hydrated and resting are the simplest and most effective parts of recovery for mild cases. There’s no need to suppress a mild cough unless it’s disrupting sleep, in which case a standard cough suppressant is reasonable.
Even if your symptoms feel manageable, it’s worth considering whether you qualify for antivirals. The benefit of those drugs is preventing a mild case from becoming a serious one, so waiting until you feel truly sick can mean missing the treatment window entirely.
Hospital Treatments for Severe Cases
When COVID-19 progresses to the point where someone needs supplemental oxygen or hospitalization, the treatment approach shifts from antivirals to controlling the body’s inflammatory response. The virus itself causes less damage at this stage than the immune system’s overreaction to it.
Dexamethasone, a corticosteroid, is the cornerstone of severe COVID-19 treatment. It reduces the runaway inflammation that can damage the lungs and other organs, and it has a proven mortality benefit. It’s typically given at a low dose (6 mg daily), though higher doses may be used in critically ill patients when clinically warranted.
For patients whose inflammation is escalating despite steroids, doctors add a second layer of immune-modulating treatment. Two classes of drugs are used here: IL-6 inhibitors (tocilizumab is preferred) and JAK inhibitors (baricitinib is preferred). Both work by tamping down specific parts of the inflammatory cascade. They’re generally given to patients with elevated markers of inflammation and worsening respiratory function, and they’re used alongside dexamethasone rather than as replacements for it.
Paxlovid Rebound
You may have heard about “Paxlovid rebound,” where symptoms or a positive test return after finishing the five-day course. This does happen, but the picture is more nuanced than early headlines suggested. In the original clinical trial, viral rebound occurred at similar rates in treated and untreated groups (about 2% in each). Some real-world studies found higher rebound rates among treated patients, ranging from 10% to 14%, though definitions of rebound varied widely across studies.
A CDC review of multiple studies found no statistically significant difference in rebound rates between people who took Paxlovid and those who didn’t. In other words, rebound appears to be a feature of COVID-19 itself, not a side effect unique to the drug. When rebound does occur, it’s generally mild and resolves on its own.
Monoclonal Antibodies
Early in the pandemic, monoclonal antibody infusions were a major treatment option. That’s no longer the case. The FDA has rescinded emergency authorizations for the main COVID antibody treatments, including bebtelovimab, sotrovimab, and the casirivimab/imdevimab combination, because the virus evolved enough that these antibodies no longer effectively neutralize circulating variants. One preventive antibody product (pemivibart) received authorization in early 2024 for people at very high risk of infection, but the treatment landscape has largely moved to oral antivirals.
Cost and Access
Paxlovid’s list price can be a barrier now that the government’s pandemic supply has been distributed. However, Pfizer operates a patient support program called PAXCESS that provides the drug at no cost to patients on Medicare, Medicaid, TRICARE, VA Community Care Network, or those who are uninsured. Commercially insured patients aren’t eligible for this specific program but may have coverage through their plan. If cost is a concern, ask your prescriber or pharmacist about assistance options before assuming you can’t afford treatment.
Early Treatment Matters Most
Across every available COVID-19 antiviral, the consistent finding is that earlier treatment produces better outcomes. The CDC recommends starting treatment as soon as possible and within five to seven days of symptom onset. If you test positive and have risk factors for severe illness, contact a healthcare provider promptly rather than waiting to see how you feel. The drugs work by slowing viral replication, and they’re most effective while the virus is still actively multiplying in the early days of infection.